Management Strategies for Obese Diabetes

Kim, Mi-Sook; Lee, Seung-Hwan

doi:2024.25.3.165

J Korean Diabetes > Volume 25(3); 2024 > Article

Focused Issue

The Journal of Korean Diabetes 2024;25(3):165-171.
DOI: https://doi.org/10.4093/jkd.2024.25.3.165 Published online September 30, 2024.

비만당뇨병의 관리 전략

김미숙, 이승환

가톨릭대학교 의과대학 서울성모병원 내분비내과

Management Strategies for Obese Diabetes

Mi-Sook Kim, Seung-Hwan Lee

Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Correspondence: Seung-Hwan Lee,
Email: hwanx2@catholic.ac.kr

Received: 14 August 2024 • Accepted: 19 August 2024

Abstract

In recent years, there has been a growing emphasis on the relationship between obesity and diabetes. An analysis of Korean data revealed that more than 75% of diabetic patients were overweight or obese, with two-thirds having abdominal obesity. Traditional treatment goals for diabetes have primarily focused on lowering blood glucose levels to prevent and treat microvascular and macrovascular complications, which is known as the glucocentric approach. However, with the recognition of the shared pathophysiology of insulin resistance in both diabetes and obesity, a weight-centric approach has emerged, particularly beneficial for patients in whom insulin resistance is a primary driver of type 2 diabetes. Of note, the overlap of various physiological aspects in diabetic patients necessitates a multicentric approach for effective type 2 diabetes management. Recent guidelines now recommend weight loss as a primary treatment goal alongside blood glucose control for overweight and obese diabetic patients, highlighting the significance of weight management in diabetes care. Medications such as glucagon-like peptide-1 (GLP-1) receptor agonist or dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist with weight-loss effects are recommended for this patient population. Ongoing research is exploring the potential of various gut hormone-based therapies, offering hope for effective weight management and improved diabetes outcomes in the growing population of obese diabetic individuals.

Key Words: Diabetes mellitus, Glucagon-like peptide-1 receptor agonists, Incretins, Obesity